You are here

  • Home
  • Archive
  • Volume 93, Issue 1
  • Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders

Article info

Article menu
Download PDFPDF
Multiple sclerosis
Original research
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders

Authors

  • Céline Louapre Sorbonne University, Paris Brain Institute - ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, CIC neurosciences, Department of Neurology, Hôpital de la Pitié-Salpêtrière, Paris, France PubMed articlesGoogle scholar articles
  • Michella Ibrahim Sorbonne University, Paris Brain Institute - ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, CIC neurosciences, Department of Neurology, Hôpital de la Pitié-Salpêtrière, Paris, France PubMed articlesGoogle scholar articles
  • Elisabeth Maillart Sorbonne University, Paris Brain Institute - ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, CIC neurosciences, Department of Neurology, Hôpital de la Pitié-Salpêtrière, Paris, France PubMed articlesGoogle scholar articles
  • Basma Abdi Sorbonne University, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Assistance Publique Hôpitaux de Paris, Laboratoire de virologie, Hôpital de la Pitié-Salpêtrière, Paris, France PubMed articlesGoogle scholar articles
  • Caroline Papeix Sorbonne University, Paris Brain Institute - ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, CIC neurosciences, Department of Neurology, Hôpital de la Pitié-Salpêtrière, Paris, France PubMed articlesGoogle scholar articles
  • Bruno Stankoff Sorbonne University, Paris Brain Institute - ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, Department of Neurology, Saint Antoine Hospital, Paris, France PubMed articlesGoogle scholar articles
  • Anne-Laure Dubessy Sorbonne University, Paris Brain Institute - ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, Department of Neurology, Saint Antoine Hospital, Paris, France PubMed articlesGoogle scholar articles
  • Caroline Bensa-Koscher Department of Neurology, The Fondation Adolphe de Rothschild Hospital, Paris, Île-de-France, France PubMed articlesGoogle scholar articles
  • Alain Créange UPEC University, Groupe Hospitalier Henri Mondor, Service de Neurologie and CRC SEP, Assistance Publique—Hopitaux de Paris, Créteil, Île-de-France, France PubMed articlesGoogle scholar articles
  • Zina Chamekh Hôpital de la Pitié-Salpêtrière, Biochemistry Department, Assistance Publique Hôpitaux de Paris, Paris, Île-de-France, France PubMed articlesGoogle scholar articles
  • Catherine Lubetzki Sorbonne University, Paris Brain Institute - ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, CIC neurosciences, Department of Neurology, Hôpital de la Pitié-Salpêtrière, Paris, France PubMed articlesGoogle scholar articles
  • Anne-Geneviève Marcelin Sorbonne University, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Assistance Publique Hôpitaux de Paris, Laboratoire de virologie, Hôpital de la Pitié-Salpêtrière, Paris, France PubMed articlesGoogle scholar articles
  • Jean-Christophe Corvol Sorbonne University, Paris Brain Institute - ICM, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, CIC neurosciences, Department of Neurology, Hôpital de la Pitié-Salpêtrière, Paris, France PubMed articlesGoogle scholar articles
  • Valérie Pourcher Sorbonne University, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Assistance Publique Hôpitaux de Paris, Service de Maladies Infectieuses, Hôpital de la Pitié-Salpêtrière, Paris, France PubMed articlesGoogle scholar articles
  • COVISEP and Bio-coco-neuroscience study group
    Google scholar articles
  1. Correspondence to Dr Céline Louapre, Sorbonne University, Paris Brain Institute - ICM, Assistance Publique Hôpitaux de Paris, CIC neurosciences, Department of Neurology, Hôpital de la Pitié Salpêtrière, Paris, Île-de-France, France; celine.louapre{at}aphp.fr
View Full Text

Citation

Louapre C, Ibrahim M, Maillart E COVISEP and Bio-coco-neuroscience study group, et al
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders
Journal of Neurology, Neurosurgery & Psychiatry 2022;93:24-31.

Publication history

  • Received April 18, 2021
  • Accepted July 16, 2021
  • First published August 2, 2021.
Online issue publication 
February 19, 2024

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage